Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Novel mRNA Detection Assay for Quantifying CD30 Expression in Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Jerry Thwin Wong, MD PhD, Thomas Ippolito, MSc, Andrea Schlosser, Francisco J. Hernandez-Ilizaliturri, MD, Vishala T. Neppalli, MD

Blood (2018) 132 (Supplement 1): 5311.

https://doi.org/10.1182/blood-2018-99-120238

Published: 2018

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

Evaluation of the Role of Radiological Imaging and Bone Marrow Biopsy in Staging of Cutaneous B-Cell Lymphoma

Pankit Vachhani, MD, Christopher J. Cancino, MD, Paul Bogner, MD, Charles L. Roche, MD, Gyorgy Paragh, MD PhD, Marcelle A. Grassi, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5326.

https://doi.org/10.1182/blood.V128.22.5326.5326

Published: 2016

Journal Articles

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Priyank P. Patel, MD, Alison Zeccola, Vishala T. Neppalli, MD, Juan J Gu, PhD, Cory Mavis, MSc, Sheila Sait, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 5122.

https://doi.org/10.1182/blood.V126.23.5122.5122

Published: 2015

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2014) 124 (21): 3031.

https://doi.org/10.1182/blood.V124.21.3031.3031

Published: 2014

Journal Articles

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Mihai Merzianu, MD, Richard Cheney, MD, Adrienne Groman, MS, George Deeb, MD, Gregory Wilding, PhD, Claudiu Cotta, MD, Ramila Amre, MD, Manjula Balasubramanian, MD, Guilherme Brandao, MD, Russell K. Brynes, MD, Sindhu Cherian, MD, Elizabeth Courville, MD, David Czuchlewski, MD, Guang Fan, MD PhD, David Grier, MD, Daniela Hoehn, MD PhD, Robert E Hutchison, MD, Kedar V. Inamdar, MD PhD, Ridas Juskevicius, MD, Prabhjot Kaur, MD, John Lazarchick, MD, Michael R Lewis, MD, Rodney R. Miles, MD PhD, Jerome B. Myers, MD PhD, Michel Nasr, MD, Hina Naushad, MD, Horatiu Olteanu, MD PhD, Attilio Orazi, MD, Vishnu VB Reddy, MD, Valentin G Robu, MD, Gratian Salaru, MD, Julie Teruya-Feldstein, MD, Neerja Vajpayee, MD, Jeffrey Vos, MD, Ling Zhang, MD, Shanxing Zhang, MD PhD, Ashley V Sedelmeyer, MHA, Vivian Arguello, MD, Le Aye, DO, Sharon Barouk, MA, Elisa F Brega, MD PhD, Richie Carpenter, BS, James E. Coad, MD, Alana DiPonio, MT, Fernandez Garcia, MS, MD, John Grantham, BS, Sinisa Ivelja, MD, Robert McKenna, MD, Kieran Sultan, MD, Matthew B Thomsen, MPH, Jie Xu, MD PhD, LoAnn Peterson, MD, Vishala T. Neppalli, MD

Blood (2014) 124 (21): 1316.

https://doi.org/10.1182/blood.V124.21.1316.1316

Published: 2014

Journal Articles

Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)

Shipra Gandhi, MD, Vishala T. Neppalli, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 5064.

https://doi.org/10.1182/blood.V122.21.5064.5064

Published: 2013

Journal Articles

IL-6 and MYC collaborate in plasma cell tumor formation in mice

Sebastian Rutsch, Vishala T. Neppalli, Dong-Mi Shin, Wendy DuBois, Herbert C. Morse, III, Hartmut Goldschmidt, Siegfried Janz

Blood (2010) 115 (9): 1746–1754.

https://doi.org/10.1182/blood-2009-08-237941

Published: 2010

Includes: Supplemental data

Journal Articles

IL-6 and Tumor Susceptibility Alleles of Strain BALB/C Cause Phenotypic Shift of MYC-Driven Lymphomas in Mice from Diffuse Large B-Cell Lymphoma (DLBCL) to Plasmacytoma (PCT)

Vishala T. Neppalli, MD, Siegfried Janz, Sebastian Rutsch, Hartmut Goldschmidt

Blood (2008) 112 (11): 5316.

https://doi.org/10.1182/blood.V112.11.5316.5316

Published: 2008

NARROW

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Novel mRNA Detection Assay for Quantifying CD30 Expression in Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Evaluation of the Role of Radiological Imaging and Bone Marrow Biopsy in Staging of Cutaneous B-Cell Lymphoma

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)

IL-6 and MYC collaborate in plasma cell tumor formation in mice

IL-6 and Tumor Susceptibility Alleles of Strain BALB/C Cause Phenotypic Shift of MYC-Driven Lymphomas in Mice from Diffuse Large B-Cell Lymphoma (DLBCL) to Plasmacytoma (PCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only